Details for Patent: 8,299,116

Which drugs does patent 8,299,116 protect, and when does it expire?

Patent 8,299,116 protects TORISEL and is included in one NDA.

Protection for TORISEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-five patent family members in twenty-seven countries.

Summary for Patent: 8,299,116

Patent landscape, scope, and claims:

Title:	CCI-779 concentrate formulations
Abstract:	This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.
Inventor(s):	Rubino; Joseph T (Towaco, NJ), Siskavich; Victoria (Lyon Mountain, NY), Harrison; Maureen M (Sugar Loaf, NY), Gandhi; Pooja (Highland Mills, NY)
Assignee:	Wyeth LLC (Madison, NJ)
Application Number:	13/206,641
Patent Claim Types: see list of patent claims	Formulation; Compound;

Drugs Protected by US Patent 8,299,116

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pf Prism Cv	TORISEL	temsirolimus	SOLUTION;INTRAVENOUS	022088-001	May 30, 2007	AP	RX	Yes	Yes	8,299,116*PED

International Family Members for US Patent 8,299,116

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	040693
Argentina	090603
Austria	385795
Australia	2003254168